Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study

PURPOSE: Metastatic breast cancer patients are the most prevalent oncology population with advanced disease facing COVID-19 pandemic. Immune responses after mRNA-based vaccination during treatment with CDK4/6 inhibitors or HER2-directed agents remain unclear. We conducted a prospective analysis to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelli, Fabrizio, Fabbri, Agnese, Botticelli, Andrea, Giannarelli, Diana, Marrucci, Eleonora, Fiore, Cristina, Virtuoso, Antonella, Berrios, Julio Rodrigo Giron, Scagnoli, Simone, Pisegna, Simona, Cirillo, Alessio, Panichi, Valentina, Massari, Annalisa, Silvestri, Maria Assunta, Ruggeri, Enzo Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662103/
https://www.ncbi.nlm.nih.gov/pubmed/38023235
http://dx.doi.org/10.3389/fonc.2023.1280416

Ejemplares similares

Ejemplares similares